By Chioma Obinna

Health & Innovation Section

Counterfeit and substandard medicines remain one of the most persistent threats to modern healthcare.

They undermine treatment outcomes, drive antimicrobial resistance, and cost legitimate supply chains billions of dollars each year.

The World Health Organization estimates that one in ten medical products in low- and middle-income countries is falsified or substandard.

In Nigeria, where the pharmaceutical market is worth more than ₦1.6 trillion, this challenge is both a health emergency and an economic liability.

As Nigeria’s medicine trade expands through wholesale markets and online pharmacies, counterfeiters have found new entry points. Fragmented data, porous borders, and inconsistent enforcement make it easy for falsified drugs to infiltrate legal channels. Strengthening the National Agency for Food and Drug Administration and Control (NAFDAC) with real-time, data-driven intelligence is now essential—not just for public health but for investor confidence and trade credibility.

Nigerian-born pharmaceutical strategist Paul-Miki R. Ibekwe, now a researcher at the University of Massachusetts Amherst, is among those rethinking how data science can reinforce medicine safety. His recently published study, “Counterfeit Medicines and Market Integrity: Strengthening Regulatory Intelligence through Predictive Analytics and Cross-Sector Collaboration” (International Medical Science Research Journal, Vol. 5 No. 8, October 2025; DOI 10.51594/imsrj.v5i8.2074*), outlines a practical blueprint for modern pharmaceutical oversight.

Building on initiatives such as the WHO’s Global Surveillance and Monitoring System and the U.S. FDA’s Sentinel Initiative, the paper shows how predictive analytics and machine learning can turn fragmented records into actionable intelligence. By fusing customs data, serialization logs, pharmacy transactions, and e-commerce metadata, regulators can detect anomalies—unusual trade routes, abnormal pricing, or suspicious shipment timing—before unsafe medicines reach patients.

Ibekwe proposes a Regulatory Intelligence Framework tailored to Nigeria’s realities. At its core lies interoperable data infrastructure linking regulators, manufacturers, and distributors through secure digital channels. Above that, analytical models score risk and prioritize inspections; at the top, decision-support dashboards enable NAFDAC, customs, and law enforcement to coordinate in real time.

The model’s defining feature is its emphasis on public–private partnerships. Logistics providers record route deviations that may signal tampering; payment processors notice clusters of suspect online transactions; manufacturers maintain serialization codes verifying product authenticity. When this information converges on a shared analytics platform, the national picture becomes clear enough to act swiftly—and at scale.

Ibekwe’s argument extends beyond public health. Predictive oversight is also a growth policy. Transparent traceability reduces operational risk and lowers insurance premiums for investors. It allows compliant domestic manufacturers to compete fairly and aligns Nigeria with international documentation standards, including those required under the African Continental Free Trade Area (AfCFTA).

By moving from paper audits to data-driven oversight, Nigeria could save enforcement costs, cut hospital losses from fake drugs, and rebuild confidence among consumers and trading partners. “Quality assurance,” Ibekwe often notes, “is an investment-climate issue.”

Powerful algorithms bring their own risks. Ibekwe’s paper stresses governance—algorithmic transparency, auditability, and human oversight—echoing the WHO’s 2025 Guidance on AI Ethics for Health. Data systems must be explainable and fair to sustain public trust. Privacy safeguards and independent monitoring are therefore treated not as afterthoughts but as pillars of credible modernization.

What gives Ibekwe’s work unusual credibility is its grounding in Nigerian constraints. His framework does not assume limitless resources; it advocates phased implementation using existing data—customs, hospital reports, manufacturer serialization—while building analytic capacity gradually. It also highlights regional cooperation through the African Medicines Agency, ensuring that Nigeria’s reforms strengthen, rather than isolate, its neighbors’ oversight systems.

Universities, he argues, should play a bridging role—training data analysts, validating regulatory algorithms, and keeping policy tied to evidence rather than politics.

A clear national pathway is emerging: integrate data systems, formalize secure information-sharing with private partners, and adopt transparent AI governance. None of this requires reinventing the wheel; it requires coordination and political will. Pharmaceutical security is no longer just health policy—it is industrial policy and consumer-protection policy combined.

If regulators, innovators, and investors embrace a predictive-analytics approach, Nigeria can lead Africa in pharmaceutical intelligence rather than react from behind. Every authentic medicine protected by data represents not only a life saved but an economy strengthened.

Paul-Miki R. Ibekwe is a pharmaceutical market analytics specialist affiliated with the Isenberg School of Management and the Institute for Applied Life Sciences at the University of Massachusetts Amherst. His research focuses on predictive analytics, regulatory intelligence, and market-integrity frameworks that strengthen equitable access to safe medicines worldwide. His October 2025 article on regulatory intelligence and counterfeit medicines is available in the International Medical Science Research Journal.